Milestone Pharmaceuticals Inc. · NASDAQ:MIST
Milestone Pharmaceuticals — ISPOR 2019
19 slides from Milestone Pharmaceuticals's conference presentation, 2019
Slide 1: Variations in Healthcare Resource Use and Expenditures by Age in Patients under Age 65 with PSVT
Variations in Healthcare Resource Use and Expenditures by Age in Patients under Age 65 Newly Diagnosed with Paroxysmal Supraventricular Tachycardia (PSVT) in the United States Naomi C. Sacks1,2; Katie Everson3; Philip L. Cyr1,4; Maia Emden1; Madison Preib1; David Wood5; Sean Pokorney6 1Precision Xtr
Slide 2: Acknowledgements
Acknowledgements We would like to acknowledge our research team and co-authors: Naomi C. Sacks, PhD Katie Everson, MS Philip L. Cyr, MPH Maia Emden, BS Madison Preib, MPH David Wood, PhD Sean Pokorney, MD, MBA Disclosure Statement: Milestone Pharmaceuticals provided funding for this study. David Woo
Slide 3: Background
Background 3
Slide 4: Background: PSVT
Background: PSVT What is PSVT? Paroxysmal supraventricular tachycardia (PSVT) is a sporadic, sudden and recurring tachycardia due to abnormal electrical pathways present in the heart at birth. • Due to its episodic nature, PSVT can be difficult to diagnose. Consequently, patients may initially be di
Slide 5: Objectives & Methods
Objectives & Methods 5
Slide 6: Study Objective
Study Objective Retrospective Employer-Based Claims Data Analysis Characterize variations in downstream healthcare costs and catheter ablations in patients age <65 (<18y, 18-40y, Objective 41-64y) newly diagnosed with PSVT. 1) Compare variations in healthcare costs by age group 3 years pre- and post
Slide 7: Methods
Methods IBM MarketScan® Commercial research database with demographic, enrollment and Data Source medical claims data Study Patients newly diagnosed with PSVT (ICD-9: 427.0; ICD-10: I47.1) and observable Population for three years before and after index diagnosis Study Years January 1, 2008 – Decemb
Slide 8: Results
Results 8
Slide 9: Number of Newly Diagnosed PSVT Patients
Sex: Female vs Male Demographic Characteristics of patients with PSVT Age <18 Number of Study Patients by Age Male Female (total n= 13,902) 12000 • 13,092 patients newly 49.4% 50.6% diagnosed with PSVT 9,988 10000 • Majority were age 41-64 Age 18-40 Number of Newly Diagnosed PSVT Patients (72.3%) •
Slide 10: Annual Per-Patient Spending
Costs Before and After PSVT Diagnosis Total Costs for Patients with PSVT Total Costs for Patients with PSVT Total Costs for Patients with PSVT Age <18 Age 18-40 Age 41-64 $25,000 $23,904 * $25,000 $25,000 $23,543 * $20,127 * $20,000 $20,000 $20,000 Annual Per-Patient Spending $15,000 $15,000 $15,000
Slide 11: Annual Per-Patient Spending Compared to Matched Controls
PSVT Patients Costs Before and After PSVT Diagnosis Compared to Matched Controls Matched Controls Total Costs for Patients with PSVT Total Costs for Patients with PSVT Total Costs for Patients with PSVT Age <18 Age 18-40 Age 41-64 $25,000 $23,904 * $25,000 $25,000 $23,543* $20,127 * $20,000 $20,00
Slide 12: Annual Per-Patient Spending: Costs of PSVT by Setting
% of Cost Increase from PSVT Costs of PSVT by Setting Age <18 Total Costs by Setting 21.8% $30,000 $25,000 $23,904 78.2% $23,543 $974 $2,610 Annual Per-Patient Spending $20,127 $20,000 $5,843 $1,241 Age 18-40 $8,738 $6,406 $15,000 17.1% $11,796 $10,203 $2,167 $10,000 $1,007 $17,087 $2,987 $6,739 $3,
Slide 13: Costs of Healthcare Encounters for Patients with PSVT
Costs of Healthcare Encounters for Patients with PSVT Average Cost per Healthcare Encounter in the Year Following PSVT Diagnosis Age <18 Age 18-40 Age 41-64 Cost per Inpatient Admission $34,371 $22,877 $30,133 Cost per ED Visit $849 $982 $1,095 Cost per Outpatient Hospital Visit $4,023 $2,352 $1,736
Slide 14: Ablations
Ablations Proportion of Patients Treated with Ablation in the Cost of Ablation by Setting Year Following PSVT Diagnosis <18 18-40 41-64 35.0% Any Setting $40,656 $32,212 $30,424 30.4% Inpatient $59,923 $41,674 $51,399 30.0% Outpatient Hospital $37,940 $30,124 $26,004 25.0% • The proportion of patien
Slide 15: Study Limitations, Summary and Conclusions
Study Limitations, Summary and Conclusions 15
Slide 16: Study Limitations
Study Limitations Study relied on claims data Laboratory, diagnostic and other test results not included in claims data Study patients limited to those under age 65 Results may not be generalizable to older patients (age 65 and above) Costs reported reflect amounts paid by insurers to providers
Slide 17: Conclusion
Conclusion • Healthcare costs increased in the year following PSVT diagnosis across all ages, consistent with the challenges in making a PSVT diagnosis. • These increases reflected costs of monitoring, ablation procedures, and medical management for PSVT • Healthcare encounters with a PSVT diagnosis
Slide 18: Contact Information
Contact Information Naomi Sacks, PhD Precision Xtract, Health Economics and Outcomes Research Boston MA naomi.sacks@precisionxtract.com 18
Slide 19: Questions?
Questions? 19